JAPANESE COHORT STUDY OF FIRST LINE CHEMOTHERAPY (CT) FOR METASTATIC COLORECTAL CANCER (MCRC) CONTAINING FLUOROPYRIMIDINE, OXALIPLATIN AND BEVACIZUMAB: EMERALD STUDY, FIRST REPORT

被引：0
|
作者：
Taku, K. [1 ]
Ohata, K. [1 ]
Yamazaki, K. [2 ]
Nishikawa, G. [1 ]
Watanabe, M. [3 ]
Sato, S. [3 ]
Oshima, T. [3 ]
Hirano, H. [1 ]
Amano, T. [4 ]
Ohashi, Y. [5 ]
机构：
[1] Shizuoka Prefectural Gen Hosp, Div Med Oncol, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Shizuoka, Japan
[3] Shizuoka Prefectural Gen Hosp, Div Surg, Shizuoka, Japan
[4] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[5] Univ Tokyo, Sch Publ Hlth, Dept Biostat, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：220 / 220
页数：1
相关论文
共 50 条
  • [41] The importance of sequence in rescheduling bevacizumab and chemotherapy administration in the first-line treatment of metastatic colorectal carcinoma (mCRC).
    Chelis, Leonidas
    Xenidis, Nikolaos
    Amarantidis, Kiriakos
    Diamantopoulos, Nikolaos
    Boutis, Anastasios L.
    Koukaki, Triantafyllia
    Michailidis, Prodromos
    Christakidis, Evagelos
    Chalvatzis, Athanasios
    Matthaios, Dimitrios
    Deftereos, Savas
    Courcoutsakis, Nikos
    Prassopoulos, Panagiotis
    Kakolyris, Stylianos
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study (vol 26, pg 3523, 2008)
    Hochster
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4697 - 4697
  • [43] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    R Zarate
    J Rodríguez
    E Bandres
    A Patiño-Garcia
    M Ponz-Sarvise
    A Viudez
    N Ramirez
    N Bitarte
    A Chopitea
    J Gacía-Foncillas
    British Journal of Cancer, 2010, 102 : 987 - 994
  • [44] TITULO: RESULTS OF BEVACIZUMAB IN COMBINATION WITH FIRST LINE AND SECOND LINE CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER
    Castano, A.
    Aristizabal, N.
    ANNALS OF ONCOLOGY, 2009, 20 : 78 - 78
  • [45] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    Zarate, R.
    Rodriguez, J.
    Bandres, E.
    Patino-Garcia, A.
    Ponz-Sarvise, M.
    Viudez, A.
    Ramirez, N.
    Bitarte, N.
    Chopitea, A.
    Gacia-Foncillas, J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 987 - 994
  • [46] EFFICACY AND SAFETY OF CETUXIMAB, OXALIPLATIN AND CAPECITABINE AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF A PHASE II STUDY
    Barroso, S.
    Sanches, E.
    Ferreira, J.
    Passos, M.
    Sa, A.
    Nabico, R.
    SottoMayor, C.
    Santo, Espirito J.
    San-Bento, R.
    ANNALS OF ONCOLOGY, 2009, 20 : 65 - 65
  • [47] Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): Results of a phase II study
    Barroso, S. A.
    Sanches, E.
    Ferreira, M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Phase II study of biweekly XELOX (capecitabine and oxaliplatin) as first line chemotherapy in elderly patients with metastatic colorectal cancer
    Grande, C., Sr.
    Quintero, G.
    Mel, J. R.
    Huidobro, G.
    Campos, B.
    Candamio, S.
    Mendez, J. C.
    Salgado, M.
    Alvarez, E.
    Casal, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer
    Uchima, Yasutake
    Nishii, Takafumi
    Iseki, Yasuhito
    Ishii, Mariko
    Hiramatsu, Soichiro
    Iwauchi, Takehiko
    Morimoto, Junya
    Kosaka, Kinshi
    Tei, Seika
    Takeuchi, Kazuhiro
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 134 - 138
  • [50] Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies.
    Hochster, HS
    Welles, L
    Hart, L
    Ramanathan, RK
    Hainsworth, J
    Jirau-Lucca, G
    Shpilsky, A
    Griffing, S
    Mass, R
    Emanuel, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 249S - 249S
12345